Back to Search
Start Over
Tumor-infiltrating lymphocytes (TILs) from patients with glioma.
- Source :
-
OncoImmunology . 2017, Vol. 6 Issue 2, pN.PAG-N.PAG. 1p. - Publication Year :
- 2017
-
Abstract
- Tumor-infiltrating lymphocytes (TILs) may represent a viable source of T cells for the biological treatment of patients with gliomas. Glioma tissue was obtained from 16 patients, tumor cell lines were established, and TILs were expanded in 16/16 cases using a combination of IL-2/IL-15/IL-21. Intracellular cytokine staining (ICS, IL-2, IL-17, TNFα and IFNγ production) as well as a cytotoxicity assay was used to detect TIL reactivity against autologous tumor cells or shared tumor-associated antigens (TAAs; i.e., NY-ESO-1, Survivin or EGFRvIII). TILs were analyzed by flow cytometry, including T-cell receptor (TCR) Vβ family composition, exhaustion/activation and T-cell differentiation markers (CD45RA/CCR7). IL-2/IL-15/IL-21 expanded TILs exhibited a mixture of CD4+, CD8+, as well as CD3+CD4−CD8−T cells with a predominant central memory CD45RA−CCR7+phenotype. TIL showed low frequencies of T cells testing positive for PD-1, TIM-3 and CTLA-4. LAG3 tested positive in up to 30% of CD8+TIL, with low (1.25%) frequencies in CD4+T cells. TIL cultures exhibited preferential usage of Vβ families and recognition of autologous tumor cells defined by cytokine production and cytotoxicity. IL-2/IL-15/IL-21 expanded TILs represent a viable source for the cellular therapy of patients with gliomas. [ABSTRACT FROM AUTHOR]
- Subjects :
- *GLIOMA treatment
*LYMPHOCYTES
*T cells
Subjects
Details
- Language :
- English
- ISSN :
- 21624011
- Volume :
- 6
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- OncoImmunology
- Publication Type :
- Academic Journal
- Accession number :
- 121612007
- Full Text :
- https://doi.org/10.1080/2162402X.2016.1252894